Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

13.8%

4 terminated out of 29 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

50%

8 of 16 completed with results

Key Signals

8 with results80% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (9)
Early P 1 (2)
P 1 (6)
P 2 (9)
P 3 (2)

Trial Status

Completed16
Terminated4
Recruiting4
Active Not Recruiting2
Not Yet Recruiting1
Unknown1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT05659381Phase 3RecruitingPrimary

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT04204811Not ApplicableActive Not Recruiting

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

NCT05429970Not ApplicableRecruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

NCT03198286Not ApplicableCompleted

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

NCT03154190Not ApplicableCompleted

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT02124421Phase 2Active Not RecruitingPrimary

HOT: HIPEC in Ovarian Cancer as Initial Treatment

NCT04811703Phase 1Recruiting

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer

NCT06315270Not Yet Recruiting

To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer

NCT05961124Phase 2Recruiting

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

NCT05025748Not ApplicableCompleted

Ask Questions (ASQ):Implementation of a Communication Intervention

NCT03811899Not ApplicableCompletedPrimary

18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)

NCT03029611Phase 2Terminated

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

NCT01551745Phase 2CompletedPrimary

Salvage Ovarian FANG™ Vaccine + Bevacizumab

NCT03297489Early Phase 1Completed

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

NCT02441140Not ApplicableTerminatedPrimary

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

NCT01196429Phase 2Completed

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

NCT02259699Not ApplicableCompletedPrimary

Ovarian Cancer Patient-Centered Decision Aid

NCT00011986Phase 3Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00301756Phase 2Completed

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

NCT01867086Phase 2CompletedPrimary

Salvage Ovarian FANG™ Vaccine + Carboplatinum

Scroll to load more

Research Network

Activity Timeline